Study guide

5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT)

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT)

Key Takeaways Explain This Topic AI

Medicare Part D mandates Medication Therapy Management (MTM) services offering an annual Comprehensive Medication Review (CMR) and quarterly Targeted Medication Reviews (TMRs).

Pharmacies performing Point-of-Care Testing (POCT) must obtain a CLIA Certificate of Waiver (CMS Form CMS-116) and strictly follow manufacturer test instructions without modification.

Authorized CLIA-waived tests in community pharmacy include blood glucose, HbA1c, lipid profiles, rapid Group A Strep, influenza A/B, COVID-19, HIV, and INR.

State test-and-treat protocols permit pharmacists to perform CLIA-waived diagnostic testing and immediately initiate prescription therapy upon positive results.

CLIA waiver quality control (QC) procedures mandate running positive and negative controls per lot/shipment, logging results, and maintaining OSHA Bloodborne Pathogens Standard compliance.

Last updated: July 2026

5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT)

MPJE Core Concept: Medication Therapy Management (MTM) is a distinct service model formalized under Medicare Part D to optimize therapeutic outcomes. Point-of-Care Testing (POCT) in community pharmacy operates under federal Clinical Laboratory Improvement Amendments (CLIA) Certificates of Waiver. Under state test-and-treat protocols, CLIA-waived diagnostic testing enables pharmacists to evaluate infectious or metabolic conditions and immediately initiate protocol-guided prescription drug therapy.

1. Medicare Part D Statutory MTM Framework

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established mandatory MTM services for targeted Medicare Part D beneficiaries.

MTM Beneficiary Eligibility Criteria

Part D sponsors must enroll targeted beneficiaries who meet three statutory thresholds:

Multiple Chronic Diseases: Typically 2 or 3 chronic conditions (e.g., Diabetes, Heart Failure, Hypertension, Dyslipidemia, Asthma/COPD).

Multiple Covered Part D Medications: Taking multiple maintenance drugs (typically between 2 and 8 covered Part D drugs).

High Annual Drug Spend: Incurring annual covered Part D drug costs that exceed a federally established annual cost threshold (e.g., $5,330 in recent plan years).

Core Service Components of MTM

MTM Component Service Description & Statutory Standard

Comprehensive Medication Review (CMR) An annual interactive, person-to-person consultation (in-person or telehealth) assessing all prescription, OTC, herbal, and dietary supplement therapies. Must include a written summary in CMS standardized format.

Targeted Medication Review (TMR) Conducted at least quarterly to address specific actual or potential medication therapy problems (e.g., drug interactions, non-adherence, high-risk medication use).

Personal Medication Record (PMR) A comprehensive document provided to the patient listing all current medications, indications, directions, and prescriber details.

Medication-Related Action Plan (MAP) A patient-centric list of actionable steps for the patient to manage their therapy, resolve problems, and track progress.

Prescriber Interventions Consultations and recommendations communicated to prescribers to resolve identified drug therapy problems (DTPs).

2. Point-of-Care Testing (POCT) & CLIA Waiver Framework

Point-of-Care Testing allows rapid diagnostic evaluation in non-traditional laboratory settings, including community pharmacies.

Clinical Laboratory Improvement Amendments (CLIA)

Federal CLIA regulations classify laboratory testing into three categories based on complexity: High Complexity, Moderate Complexity, and Waived .

CLIA Certificate of Waiver: Pharmacies performing POCT must obtain a Certificate of Waiver from CMS by submitting Form CMS-116 and paying biennial registration fees.

Waived Test Definition: Tests cleared by the FDA for home use or simple, un-monitored tests that have an insignificant risk of an erroneous result.

Strict Compliance Rule: To maintain CLIA-waived status, the pharmacy must follow manufacturer instructions exactly without modification . Any modification of test procedures elevates the test to High Complexity, subjecting the pharmacy to stringent federal lab regulations.

3. Authorized CLIA-Waived Tests & Protocol Prescribing Actions

CLIA-Waived Test Specimen Matrix Clinical Target / Indication Protocol-Driven Prescribing Action

Rapid Group A Strep Throat swab Pharyngitis / Streptococcus pyogenes Initiate Amoxicillin or Azithromycin (if penicillin-allergic) per protocol.

Rapid Influenza A/B Nasopharyngeal / Nasal swab Influenza viral infection Initiate Oseltamivir (Tamiflu) or Baloxavir (Xofluza) within 48 hours of symptom onset.

Rapid COVID-19 Ag/PCR Nasal / Nasopharyngeal swab SARS-CoV-2 infection Initiate Nirmatrelvir/ritonavir (Paxlovid) within 5 days of symptom onset for high-risk patients.

Blood Glucose & HbA1c Capillary blood (fingerstick) Diabetes monitoring / screening Report values to PCP; adjust glycemic agents under valid CPA.

Lipid Panel (TC, HDL, Trig, LDL) Capillary blood (fingerstick) Dyslipidemia screening Evaluate ASCVD risk; initiate statin therapy under valid CPA or statewide protocol.

International Normalized Ratio (INR) Capillary blood (fingerstick) Warfarin anticoagulation monitoring Adjust Warfarin dose and manage dietary Vitamin K guidance under CPA.

Rapid HIV 1/2 & HCV Fingerstick blood / Oral fluid HIV / Hepatitis C screening Provide preliminary screening result; refer positive cases immediately for confirmatory diagnostic testing.

4. Test-and-Treat Protocols & Red-Flag Referrals

State legislatures increasingly enact "Test-and-Treat" statutes permitting pharmacists to perform CLIA-waived POCT and immediately prescribe target anti-infective medications.

Protocol Prescribing Workflow

Patient Screening: Evaluate symptom duration (e.g., flu symptoms < 48 hours, COVID symptoms < 5 days).

Execute Waived Test: Perform CLIA-waived rapid antigen or molecular test following strict manufacturer protocol.

Interpret Result & Prescribe: If positive, initiate protocol-specified prescription therapy; if negative, provide supportive care guidance.

Mandatory Physician Referral (Red Flags): Pharmacists must immediately refer patients to an urgent care or emergency department if red-flag symptoms are present:

  • High fever (>103°F / 39.4°C) unresponsive to antipyretics
  • Severe respiratory distress, shortness of breath, or oxygen saturation < 92%
  • Immunocompromised state (e.g., active chemotherapy, advanced HIV, organ transplant)
  • Symptoms suggesting severe invasive illness or sepsis
  • 5. Quality Control, Safety, and OSHA Compliance
  • CLIA Quality Control (QC) Practices

Good Laboratory Practices (GLP): Pharmacies must maintain a dedicated testing area, verify expiration dates of test kits and reagents, and perform routine instrument calibration.

External Quality Control Testing: Run positive and negative controls provided in test kits with each new lot number, each new shipment, and whenever storage temperatures deviate from manufacturer specifications. All QC results must be logged.

OSHA Bloodborne Pathogens Standard Compliance

Pharmacies conducting capillary blood testing (glucose, lipid, INR, HIV) must strictly comply with OSHA regulations:

Written Exposure Control Plan: Maintained and updated annually.

Universal / Standard Precautions: Treating all human blood and body fluids as infectious.

Engineering & Work Practice Controls: Mandatory use of single-use, auto-disabling safety lancets and immediate disposal into rigid, puncture-resistant Sharps Containers .

Hepatitis B Vaccination: Must be offered free of charge to all employees with occupational exposure risk within 10 working days of initial assignment.

Loading diagram... Pharmacy POCT & Test-and-Treat Clinical Decision Algorithm